On Monday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -5.06% from the last session, before settling in for the closing price of $11.26. Price fluctuations for OCUL have ranged from $5.78 to $16.44 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 8.51% over the last five years. Company’s average yearly earnings per share was noted -19.10% at the time writing. With a float of $186.31 million, this company’s outstanding shares have now reached $213.05 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 12.55%, while institutional ownership is 79.29%. The most recent insider transaction that took place on Nov 24 ’25, was worth 22,611. In this transaction Chief Strategy Officer of this company sold 1,878 shares at a rate of $12.04, taking the stock ownership to the 277,860 shares. Before that another transaction happened on Nov 24 ’25, when Company’s insider sold 19,530 for $12.04, making the entire transaction worth $235,141. This insider now owns 3,157,960 shares in total.
Ocular Therapeutix Inc (OCUL) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.29 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.22) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -19.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.52% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 7.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.41 in one year’s time.
